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Abstract 
The fact that during 2009 an estimated 2.6 million people were infected with 
human immunodeficiency virus (HIV) indicates additional methods for preventing HIV 
infections, including an effective pre-exposure chemoprophylaxis, are sorely needed. 
Promising attempts at developing a pre-exposure chemoprophylaxis for HIV have 
included the development of a microbicide gel and use of oral antiretroviral medication. 
Now is not too early to begin planning for resource allocation and to explore the ethical 
arguments in favor of global distribution of pre-exposure chemoprophylaxis for people 
who have no other options for HIV prevention.  
People living in developed and developing countries alike are likely to benefit 
from pre-exposure chemoprophylaxis as an individualized option to gain control over 
their own risks for developing HIV infections. Whether individual risk factors for HIV 
exposure include not knowing a sexual partner’s HIV status, a serodiscordant 
relationship, having multiple sexual partners, substance abuse, injection drug use, or 
occupational exposure through commercial sex work, obtainable pre-exposure 
chemoprophylaxis may prove to be the only method available for those at risk who have 
no other options for HIV prevention.  
A good first step for governments, non-governmental organizations, insurance 
companies, and healthcare providers to take is to consider the ethical arguments 
promoting the global distribution of pre-exposure chemoprophylaxis for HIV. This paper 
will explore the subpopulations likely to benefit from pre-exposure chemoprophylaxis for 
HIV, the arguments for and against global distribution of pre-exposure 
chemoprophylaxis, ethical considerations for distribution, and leadership guidance for 
public health in a new era of HIV prevention.  
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Introduction 
 The fact that during 2009 an estimated 2.6 million people worldwide were infected 
with HIV (Joint United Nations Programme on HIV/AIDS, 2010) indicates additional 
methods for preventing HIV infection, including an effective pre-exposure 
chemoprophylaxis, are sorely needed. Now is not too early to begin planning for 
resource allocation and to explore the ethical obligations governments have to promote 
global distribution of pre-exposure chemoprophylaxis for people who have limited or no 
options for HIV prevention.  
 This paper will explore the domestic and international subpopulations likely to 
benefit from pre-exposure chemoprophylaxis for HIV, the arguments for and against 
global distribution of pre-exposure chemoprophylaxis, ethical considerations for 
distribution, and leadership guidance for public health leaders in a new era of HIV 
prevention.  
 
Literature Review 
In the 1980’s, as soon as scientists identified the human immunodeficiency virus 
(HIV), the virus which causes AIDS (acquired immunodeficiency syndrome), they began 
working on ways to treat those living with the virus and searched for methods to prevent 
new infections. Progress to create a vaccine to protect against HIV has been slow, 
riddled with many challenges (Johnston & Fauci, 2008) and appears years, if not 
decades, away. After the discovery of potent antiretrovirals to treat HIV infection, 
application of these agents to prevent infection when administered just after or prior to 
HIV exposure was explored.  
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Preventing HIV infections with pre-exposure chemoprophylaxis. 
Studies with rhesus macaques and varying doses of the ARVs emtricitabine 
(FTC) and tenofovir disoproxil fumarate (TDF) yielded a combination effective at 
preventing simian immunodeficiency virus (SIV) in monkeys rectally exposed to SIV 
(García-Lerma et al., 2008). SIV is a retrovirus like HIV that causes infections in 
primates that are similar to HIV infections in humans. The monumental finding that SIV 
infections could be prevented in one species of primates suggests the feasibility of 
prevention of HIV infections in humans.  
A series of animal model studies led to human testing of pre-exposure 
chemoprophylaxis for HIV. Promising attempts at developing a pre-exposure 
chemoprophylaxis for HIV in humans have included the development of a microbicide 
gel tested in women and use of an ARV pill studied in men who have sex with men 
(MSM). A microbicide gel with active ingredient TDF showed a 39% reduction in HIV 
incidence among South African women inserting the gel vaginally prior to and after 
sexual intercourse (Abdool Karim et al., 2010). A multinational clinical trial providing a 
daily FTC/TDF tablet to high risk, HIV uninfected MSM found the medication reduced 
the incidence of HIV by 44% (Grant et al., 2010). In both trials, efficacy was much 
higher among those participants adherent to their assigned interventions. Among 
women who reported high adherence to their microbicide gel regimen, the rate of HIV 
incidence was 54% lower than in the placebo arm (Abdool Karim et al., 2010). Men 
reporting the highest adherence rate to their FTC/TDF pill regimen experienced a rate of 
infection that was 73% that of less adherent participants, according to post-hoc 
analyses (Grant et al., 2010). These landmark studies have inspired new approaches 
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regarding the prevention of HIV infection, pairing both behavioral and biological 
interventions to yield highly active prevention strategies. 
Low-cost behavior interventions have proven effective at preventing transmission 
of HIV. Behavioral changes including reducing the number of sexual partners (Shelton 
et al., 2004), correctly using latex condoms (Roper, Peterson, & Curran, 1993), and 
participating in syringe and needle exchange programs (Watters, Estilo, Clark, & 
Lorvick, 1994) are all proven methods for reducing HIV exposure. Additionally, male 
circumcision has shown a protective effect against HIV (Auvert et al., 2005; Bailey et al., 
2007; Gray et al., 2007). Not everyone at risk is able to apply these low-cost 
interventions to protect themselves from HIV exposure, which further affirms the need 
for pre-exposure chemoprophylaxis to prevent HIV infections in people with no other 
options for protection.  
 
Why pre-exposure chemoprophylaxis is needed. 
A communicable disease transmitted by humans to other humans, HIV infects 
individuals who may be unaware they are infected and unwittingly infect sexual or 
needle sharing partners. In other cases, HIV infected persons may know they are 
infected but fail to disclose their HIV status. Alternatively, both partners in an HIV 
serodiscordant partnership may be aware of the infected partner’s HIV infection but still 
choose not to take measures to limit HIV exposure. Therefore, there are a number of 
different situations where pre-exposure chemoprophylaxis to prevent HIV infection can 
be applied. 
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One study of HIV serostatus disclosure in southern China found 94.8% of study 
participants disclosed their positive HIV status to a regular sexual partner while only 
13.0% of respondents shared their HIV serostatus to casual sexual partners (Wang et 
al., 2010). In the French Antilles and French Guiana, 84.6% of survey respondents in a 
relationship had disclosed their HIV status to a steady partner (Bouillon et al., 2007). 
Those in steady and casual relationships with an HIV positive partner who has not 
revealed his or her serostatus are at risk of becoming infected with HIV if condoms are 
not appropriately used during intercourse. Research shows people in concurrent 
relationships do not always use condoms with a regular or steady sexual partner 
(Kenyon, Boulle, Badri, & Asselman, 2010). Access to pre-exposure chemoprophylaxis 
would protect HIV negative individuals during HIV exposure by a regular or casual 
sexual partner who failed to disclose or was unaware of his or her serostatus. 
 
 Women and gender inequalities. 
 Slightly more than half of people in the world who are living with HIV are women 
(Joint United Nations Programme on HIV/AIDS, 2010). This statistic represents a 
significant increase over the early years of the epidemic when most people diagnosed 
with HIV were male. The increase in the number of HIV infections among woman may 
serve as an indicator of where the epidemic is headed. Biological differences between 
women and men make women more susceptible to HIV infection (Quinn & Overbaugh, 
2005).  
 In some parts of the world women are given little or no opportunity to choose their 
own marriage or sexual partners (Lenke & Piehl, 2009) and each year women are 
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forced to marry men living with HIV whose serostatus has not been disclosed to them. 
Further, married women in many developing countries are often under immense societal 
and familial pressure to have sexual intercourse with their husbands and to produce 
male children (Bhattacharya, 2004). In serodiscordant heterosexual couples in which 
the male partner is living with HIV, the female partner is faced with a difficult decision. If 
she is even given a choice, the female partner must decide whether to fulfill what her 
community views as her role as a woman and engage in sexual activity that could lead 
to pregnancy, putting her health and that of her unborn child at risk for acquiring HIV. A 
pre-exposure chemoprophylaxis would protect women in serodiscordant relationships 
against HIV.  
 Every year serodiscordant couples who want to have children face limited options 
to protect the HIV negative partner during the conception process. Few options such as 
sperm-washing and artificial insemination are available but are cost prohibitive or 
unavailable in the places where many couples live (Matthews, Baeten, Celum, & 
Bangsberg, 2010). The concept of periconception pre-exposure chemoprophylaxis for 
serodiscordant couples who want to conceive suggests ARV medications could be 
taken during the time in which the couple is having sexual intercourse with the intent to 
conceive (Matthews et al., 2010). While data supporting this method is not yet available 
(Matthews et al., 2010) future research may explore its efficacy. Use of periconception 
pre-exposure chemoprophylaxis would be an example of a situation in which a person 
may only elect to take pre-exposure chemoprophylaxis for a limited amount of time and 
after conception may resume regular condom use as a primary method of HIV 
prevention.  
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 In relationships or situations in which one partner is unable to negotiate condom 
use during sexual intercourse, an alternative method to prevent HIV infection is needed 
(Denton et al., 2008). A survey of women in Vancouver, Canada who engage in 
commercial sex work found a quarter of the women were pressured to engage in sexual 
activity without using a condom (Shannon et al., 2009). A pre-exposure 
chemoprophylaxis would allow an individual to protect him or herself from HIV without 
requiring action or consent from his or her sexual partner (Denton et al., 2008).  
 When the female condom was first introduced in Africa as a method for HIV 
prevention, it was negatively viewed by some men as an unwanted source of female 
empowerment that would take away some of men’s power and control in sexual 
relationships (Kaler, 2001). Further, rumors that female condoms threatened the health 
of men who had sexual intercourse with women who used them spread false truths 
(Kaler, 2001). These rumors may have been initiated in an effort to intimidate women 
from attempting to use the female condom. Other people felt the introduction of the 
female condom was a positive occurrence as it was the first intervention available to 
women that would allow women to take control of their own sexualities, thus allowing 
them to make their own decisions regarding their risks for acquiring sexually transmitted 
infections (STIs) (Kaler, 2001) and unwanted pregnancies. However, the female 
condom is not invisible to male sexual partners (Kaler, 2001) so a woman who wants to 
use it during sexual intercourse is still reliant upon her male partner’s acceptance of it. 
This renders the female condom an imperfect option for the prevention of HIV infections 
in women. A pre-exposure chemoprophylaxis would eliminate the problem of visibility 
women may experience from using the female condom for HIV prevention.  
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Ethical issues surrounding women and HIV. 
The Public Health Leadership Society (2002) states as one of its principles for 
the ethical practice of public health that “public health should advocate and work for the 
empowerment of disenfranchised community members, aiming to ensure that the basic 
resources and conditions necessary for health are accessible to all” (Public Health 
Leadership Society, 2002, p. 7). In the spirit of this principle, public health leaders who 
advocate for women at risk for acquiring HIV infections who have access to few if any 
methods for HIV prevention are working to ensure resources for HIV prevention are 
available for all. The “rescue principle” finds it intolerable when a society allows 
individuals to die when their lives could have been saved had more money been spent 
on their healthcare (Beauchamp & Childress, 2001). In an era of technological 
advances in medicine, it can be tough to decide exactly how much money is a 
reasonable amount to spend on healthcare costs (Dworkin, 1992). This principle can be 
applied in the example of providing pre-exposure chemoprophylaxis to women who 
have no other options for HIV prevention. If a woman who would have benefited from 
pre-exposure chemoprophylaxis becomes infected with HIV and then dies from AIDS 
related complications because she was unable to afford the preventative medication 
and her government failed to provide it, the rescue principle would have been fulfilled. In 
order to provide pre-exposure chemoprophylaxis for those most at risk for acquiring HIV 
infections, developing countries would likely have to rely on wealthier countries for 
financial support. Generally, when wealthier countries act to enhance global health 
efforts in less developed countries, their participation is often in support of their own 
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interests or in reaction to humanitarian instincts (Gostin & Taylor, 2008). While the US 
and other nations continue to donate money and resources for the treatment of and 
prevention of HIV in less developed countries, considering the plight of people living in 
other places around the world who are unable to advocate for themselves is important 
when deciding how to allocate resources.  
 
Cost effectiveness of pre-exposure chemoprophylaxis. 
When deciding whether providing pre-exposure chemoprophylaxis for HIV is a 
reasonable expectation for government funding, estimates from mathematical models 
provide data to evaluate the cost effectiveness of the intervention. Using actual costs 
from 2006, the estimated US monthly cost of daily FTC/TDF pre-exposure 
chemoprophylaxis, the same medication used by Grant et al., (2010), and a portion of 
quarterly blood test costs is $753 per person (Paltiel et al., 2009). While this estimated 
cost is great, one must consider it against the monthly cost of ARV treatment for HIV 
infection which ranges from $1,100 to $3,300 each month (Paltiel et al., 2009). 
When pre-exposure chemoprophylaxis is used, some of the infections prevented are 
due to a direct result of pre-exposure chemoprophylaxis use; the remaining infections 
would be prevented indirectly due to an overall reduction in the community’s HIV 
prevalence because fewer people would be exposed to the virus since some people 
would be taking preventative treatment (Desai et al., 2008).  
A mathematical model employed to estimate the potential effects of combining 
risk behavior reduction with a pre-exposure chemoprophylaxis for preventing HIV 
infections in sub-Saharan Africa estimated 2.7 to 3.2 million new infections could be 
prevented over ten years at an estimated cost of $US 2 billion (Abbas, Anderson, & 
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Mellors, 2007). Using World Health Organization [WHO] cost-effectiveness ratios 
indicating that very cost-effective interventions are those which cost less than the 
amount of per capita gross domestic product per year of life saved, researchers 
calculated the cost-effectiveness of both oral and vaginal gel pre-exposure 
chemoprophylaxis interventions in South Africa (Park, 2011). Both interventions were 
found to be very cost-effective when implemented in South Africa and returned an 
excellent value for the money spent (Park, 2011; Pretorius et al., 2010). If the cost of 
pre-exposure chemoprophylaxis was reduced, the intervention targeted at very high risk 
populations, and the efficacy increased to more than 70%, pre-exposure 
chemoprophylaxis would represent cost-savings in South Africa (Park, 2011). Another 
mathematical modeling reveals PrEP is cost-effective in South Africa at reducing HIV 
incidence and most effective when specifically targeted at women aged 15-35 and 
combined with a universal test and treat campaign to provide frequent HIV testing for 
community members along with ARV treatment for those who test positive (Pretorius et 
al., 2010). One method to improve the cost-effectiveness of an HIV prevention 
intervention may be to identify sexual networks and targeting the intervention at those 
most at risk for HIV infection (DeGruttola, Smith, Little, & Miller, 2010).  
 
Acceptability of pre-exposure chemoprophylaxis. 
As with any public health intervention, if the community or target audience does 
not find the intervention acceptable or feasible, the implementation will not be 
successful regardless of its cost. In the case of pre-exposure chemoprophylaxis for HIV, 
research participants and clinicians generally found the preventative treatment to be an 
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acceptable intervention. In a trial of men and women using a rectal microbicide gel to 
prevent the transmission of HIV, 75% of participants indicated they would be willing to 
use the gel after the trial if it would prevent HIV transmission despite experiencing 
feelings of discomfort and dislike while using the gel (Anton, 2011). A randomized 
controlled trial of HIV negative female participants assigned to receive both oral and 
vaginal forms of pre-exposure chemoprophylaxis found 93% of women would take the 
oral tablet in the future while 83% would be willing to use the vaginal gel (Hendrix, 
2011). Differences were seen between women in different geographic locations as more 
African study participants favored the gel than US participants, citing that the gel 
improved sexual pleasure (Hendrix, 2011). Physicians in Massachusetts surveyed in 
2010 revealed most were aware of both oral and gel formulations of pre-exposure 
chemoprophylaxis but more would consider prescribing the gel formulation due largely 
to a perception that there were fewer potential side effects (Mayer, Mimiaga, White, 
Krakower, & Vanderwarker, 2011).  
 
Potential adverse consequences of pre-exposure chemoprophylaxis. 
While the benefits of pre-exposure chemoprophylaxis are great, they must be 
weighed against the potential for serious adverse effects. Serious side effects of 
FTC/TDF include the possibility of liver and kidney problems as well as the loss of bone 
mineral density (Gilead Sciences, 2011). The most frequently experienced side effects 
are: “diarrhea, nausea, fatigue, headache, and dizziness” (Gilead Sciences, 2011). Of 
the participants in the oral pre-exposure chemoprophylaxis trial conducted by Grant et 
al. (2010), 1% of participants in the treatment arm experienced bone fractures 
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compared to <1% of participants taking the placebo. Additionally, a statistically 
significant number of creatinine level elevations occurred among participants taking the 
active study drug (Grant et al., 2010). Among users of a rectal, TDF microbicide gel, the 
most common adverse events were events of lower gastro-intestinal tract distress 
(Anton, 2011). Laboratory markers of renal disease would need to be assessed 
quarterly to detect any adverse effects from FTC/TDF or TDF (Paltiel et al., 2009). Due 
to the possible side effects and requisite laboratory monitoring, an individual wishing to 
take FTC/TDF or TDF for pre-exposure chemoprophylaxis must do so under the care of 
a healthcare provider.  
Taking a medication to prevent HIV infection would not negate the necessity for 
regular HIV testing, laboratory testing to monitor medication side effects, and visits with 
a healthcare provider. Prior research has shown there is potential for individually and 
community-acquired drug resistance should an individual taking pre-exposure 
chemoprophylaxis become infected with HIV (Desai et al., 2008; Mayer & Venkatesh, 
2010). If someone was infected with HIV and developed resistance to the pre-exposure 
antiretroviral chemoprophylaxis agent(s), he or she could pass a resistant strain of the 
virus to a sexual partner or developing fetus before being diagnosed (Mayer & 
Venkatesh, 2010). Frequent testing for HIV antigen would limit the amount of time an 
individual was taking pre-exposure chemoprophylaxis before realizing he or she had 
been infected with the virus and would also limit the length of time the HIV infection was 
being treated without optimal ARV therapy (Mayer & Venkatesh, 2010). While testing for 
HIV antigen after every potential exposure is not practical, routine testing is warranted. 
Acquired resistance at the time of infection from either a partner with a resistant strain of 
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HIV or from taking pre-exposure chemoprophylaxis at the time of infection limits ARV 
treatment options down the road because the medication(s) used during pre-exposure 
chemoprophylaxis may no longer be an effective option for treating the infection (Desai 
et al., 2008).  
If an effective pre-exposure chemoprophylaxis for HIV is FDA approved but not 
affordable or widely available, HIV-negative individuals hoping to take pre-exposure 
chemoprophylaxis may seek to obtain the medication from a community source rather 
than from a prescription written by a healthcare provider. Taking the antiretroviral 
medication prescribed to a partner, friend, or family member living with HIV not only has 
the potential to decrease the potency of the antiretroviral regimen for the person for 
which it was prescribed, but may lead to sporadic and ineffective use (Liu, Grant, & 
Buchbinder, 2006). Additionally, the quality of medication obtained without a 
prescription from a non-FDA approved supply cannot be monitored and may be 
ineffective or harmful (Liu et al., 2006).  
Aside from the potential for adverse physical side effects from taking pre-
exposure chemoprophylaxis, there exist potential behavioral consequences as well. 
Providing pre-exposure chemoprophylaxis along with risk reduction counseling and 
regular HIV testing is not likely to encourage an increase in high risk behaviors by those 
taking the medication. Martin et al. (2004) provided post-exposure prophylaxis (PEP) 
and risk reduction counseling to individuals after nonoccupational high risk exposure to 
HIV then followed the PEP recipients for twelve months. It was concluded receipt of 
PEP did not lead to an increase in high risk behaviors (Martin et al., 2004). Additionally, 
taking PEP after HIV exposure did not lead to an increase in risky behaviors among 
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MSM in Brazil (Schechter et al., 2004). However, there is possibility for a potential 
increase in the frequency of other sexually transmitted infections and/or unplanned 
pregnancies if individuals using pre-exposure chemoprophylaxis elect to decrease or 
discontinue condom use because they feel the chemoprophylaxis protects them from 
HIV infection and therefore condom use is no longer warranted. Providing extensive risk 
reduction counseling and condoms for individuals taking pre-exposure 
chemoprophylaxis is one step towards counteracting this behavior (Vissers, Voeten, 
Nagelkerke, Habbema, & de Vlas, 2008).  
An additional adverse consequence of taking pre-exposure chemoprophylaxis is 
the possibility of experiencing social harms. Women may be fearful of disclosing to their 
male sexual partners that they wish to take action to prevent HIV infection and/or that 
they feel their male partners may be exposing them to HIV. Other worries a woman may 
experience could be about her partner or someone else seeing her when she is taking 
her pre-exposure chemoprophylaxis or fears of someone finding the medication or gel 
among her belongings and making assumptions that she is HIV positive, unfaithful to 
her sexual partner, or thinks that her partner might be HIV positive. While these are 
valid concerns the potential problems they present are easier to avoid than the problem 
of a female condom being visible to a male sexual partner and may not outweigh the 
benefits gained from pre-exposure chemoprophylaxis when no other options exist.  
 
Distribution of pre-exposure chemoprophylaxis. 
After weighing the potential benefits and risks of pre-exposure 
chemoprophylaxis, guidance for healthcare providers may help determine which 
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patients are the best candidates to receive the preventative intervention. Official 
guidelines for the use of pre-exposure chemoprophylaxis for HIV are currently being 
developed by the U.S. Public Health Service with input from the Centers for Disease 
Control [CDC] and other experts (Centers for Disease Control and Prevention [CDC], 
2011). Meanwhile, the CDC has published interim guidelines for the use of pre-
exposure chemoprophylaxis in MSM (CDC, 2011). Although the guidelines promote pre-
exposure chemoprophylaxis use in men only, FTC/TDF has been used along with other 
medications to treat HIV infection in women and should theoretically work as a 
prevention option for women as well. After confirming the lack of HIV antibodies and 
assessing any symptoms of acute HIV infection, the CDC recommends pre-exposure 
chemoprophylaxis for MSM who are, “at substantial, ongoing, high risk for acquiring HIV 
infection” (CDC, 2011). Regular follow-up visits with a healthcare provider are 
recommended to assess laboratory values and HIV serostatus, provide adherence 
counseling and condoms, and evaluate STI symptoms and screening results (CDC, 
2011).  
Prior to the discovery of pre-exposure chemoprophylaxis, models were 
developed for the distribution of PEP which may be relevant when considering how to 
distribute a preventative treatment. Some PEP models have been based on risk 
exposure and epidemic profiles. Lurie, Miller, Hecht, Chesney, and Lo, (1998) 
suggested PEP should be included as only one component in a comprehensive 
program to prevent HIV infections. Further, due to the large number of HIV exposures 
each day, prevention programs including PEP for nonoccupational exposures should 
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only be made available to people with sporadic exposure and living in the cities with the 
highest prevalence of the virus (Lurie, et al., 1998).  
Prior research to find an effective pre-exposure chemoprophylaxis has been 
partially funded by the United States government (Grant et al., 2010) while future 
research will likely also receive federal funding. Beauchamp and Childress (2001) 
explained the role of government funded research as one that works to find a cure or 
treatment for an ailment rather than an obligation to provide that cure or treatment for 
everyone at risk. The arguments of Beauchamp and Childress (2001) explain 
stakeholders should only expect a “decent return” on the government funded research 
rather than a “full return.” In this case, a decent return would be the identification of an 
effective pre-exposure chemoprophylaxis while a full return would be the provision of 
preventative medication worldwide. While the government stakeholders may be 
satisfied with a decent return on their investment into pre-exposure chemoprophylaxis 
research, those stakeholders touched more directly by the virus may find it necessary to 
lobby the US government in hopes law makers will allocate funding to provide a better 
return on their investment in pre-exposure chemoprophylaxis research discoveries. 
Simply knowing a preventative medication exists is not enough for people at risk for HIV 
infection who have no options for protection from HIV. The public may consider the 
attitudes of public servants towards a decent versus full return when electing 
government leaders. When government leaders remain silent or take no action to 
address the HIV epidemic in their countries, a leadership crisis is at hand (Achmat, 
2006). The public health leadership competency framework describes the need for a 
public health leader who “guides the community and organization in assisting and 
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supporting legislative deliberation and action on public health issue” (National Public 
Health Leadership Development Network, 2005). By prompting legislators to debate and 
support pre-exposure chemoprophylaxis for HIV, public health leaders will work towards 
promoting the prevention intervention for their communities.  
 
Ethical Considerations. 
Ethical theories provide a framework for public health leaders to consider when 
evaluating whether or how to incorporate pre-exposure chemoprophylaxis into public 
health programming, deciding the best distribution plan for the preventative medication 
or gel, or debating how much funding should be designated for such a costly 
intervention. Moral doctrines and ethical theories offer a template that can be used to 
evaluate the potential consequences of actions public health leaders may take by 
deciding to provide new HIV prevention strategies. Also, consideration of ethical 
theories can assist public health leaders during their appeals to lawmakers or when 
communicating programming goals to community stakeholders. A framework for public 
health leaders to initially consider is one which evaluates the leaders’ actions to 
promote HIV prevention strategies. The moral theory consequentialism indicates that 
the end result of an action is what determines its moral value (Holland, 2007). 
Utilitarianism, an example of the moral theory consequentialism, states a position that in 
any situation, the right thing to do is that action which has the best consequences and 
brings the greatest well-being, benefit, or welfare (Holland, 2007). When considering 
whether to designate money or resources for HIV prevention, the best action for 
legislators to take would be to set aside funds for HIV prevention since that action 
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brings about the maximal benefit of preventing new infections. Of course, with limited 
resources and the equally important competing priority of providing expensive 
antiretroviral medications for people already infected with HIV, both causes deserve 
consideration during funding discussions and planning. Dialogue surrounding policy 
debate will hopefully make those present more aware of the issues at hand, gain insight 
into arguments from both sides, and consider viewpoints they had not previously 
thought of (Gert, Culver, & Clouser, 2006). Presenting mathematical models to the 
policy makers is an additional step to include during policy discussions as the models 
demonstrate how pre-exposure chemoprophylaxis could realistically reduce HIV 
incidence rates in various communities worldwide (Vissers et al., 2008).  
When implementing new HIV prevention strategies, public health leaders may be 
most effective in their efforts when they consider not only those people they are trying to 
protect, but also those already infected with the virus. Given that in 2009 only slightly 
more than one-third of eligible people living with HIV in countries designated as low or 
middle income were receiving ARV treatment (Joint United Nations Programme on 
HIV/AIDS, 2010), concern may exist over proposals to provide free or affordable pre-
exposure chemoprophylaxis when the current unmet ARV treatment need is so great. 
Balancing the needs and concerns of both those at risk and already infected is 
important (Mayer & Venkatesh, 2010). Worth noting is an observed ineffective allocation 
of funds designated for HIV/AIDS related needs by leadership in countries experiencing 
a deficit of appropriate data for public health leaders to consult on the cost-effectiveness 
of particular interventions before deciding how to best disperse funds (Forsythe et al., 
2009). Public health leaders would benefit from consulting available epidemic profiles 
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and other available community data before deciding how to fairly allocate resources 
(Kass, 2001; Public Health Foundation, 2010) for pre-exposure chemoprophylaxis in 
their communities. Core competencies for public health professionals specific to public 
health leaders include the analytical and assessment skills necessary to work towards 
eliminating data source gaps, incorporating data into the resolution of public health 
issues, and considering analyses of cost effectiveness, benefits, and utility when 
planning and prioritizing public health programs (Public Health Foundation, 2010). 
Further, the National Public Health Leadership Development Network (2005) includes 
as part of its leadership competency framework the abilities of public health leaders to 
initiate and facilitate conversations, strategies, tactical assessments, and tactical 
program plans. Achieving these competencies will better allow public health leaders to 
make informed decisions during program planning to implement public health programs 
to distribute and promote pre-exposure chemoprophylaxis for HIV in ways that are cost-
effective and based on complete and accurate data of community epidemic profiles. 
When HIV prevention programs use resources in the most effective manner possible, 
more program participants will benefit. Novotny (2006) argued the US government has 
a moral responsibility to respond to global health needs, especially when the disease 
burden is high. One mechanism by which the US can use its many resources to 
contribute to global health is by providing public health leadership (Novotny, 2006).  
 
The need for leadership. 
Public health leaders can contribute to global health by setting an example for 
the best ways to incorporate pre-exposure chemoprophylaxis into current HIV 
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prevention programs. One reaction to advances in clinical science is often the 
development and dissemination of new guidelines for clinical practice (Eagle, Garson, 
Beller, & Sennett, 2003) such as the interim guidelines for pre-exposure 
chemoprophylaxis released by the CDC. Eagle et al., (2003) acknowledged that the 
creation of evidence-based guidelines is not sufficient for implementing new, 
recommended best practices based on scientific discoveries. Leadership is the 
important piece that links clinical science with clinical practice (Eagle et al., 2003). One 
project aimed at improving the implementation of clinical practice guidelines found 
effective leadership with the skills to both motivate peers and influence administration, 
was critical in changing behaviors that improved clinical care based on new 
recommendations (Eagle et al., 2003). Whether public health leaders are responsible 
for providing direct patient care for people at risk for HIV infection, coordinating an HIV 
prevention research project, or managing programs targeted at people at risk for 
acquiring HIV, effective leadership is key to ensure advances in HIV prevention such as 
pre-exposure chemoprophylaxis reach the people who would benefit the most.  
 
Leadership considerations. 
Public health leaders are needed to guide organizations that are conducting 
research, providing patient care, or implementing HIV prevention programs. As public 
health programs and advocates face expected and unexpected challenges in a new era 
of HIV prevention strategies, public health leaders and advocates may benefit from 
calling upon proven leadership strategies to ease their daily work and optimize team 
performance. Recognizing that leaders are closely watched by their subordinates who 
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take cues from their leaders’ emotions, public health leaders are likely to achieve better 
results when practicing emotional intelligence in the workplace (Goleman, Boyatzis, & 
McKee, 2002). Self awareness (recognizing personal challenges, motivators, and 
values), self management (ability to control emotions and provide controlled energy), 
social awareness (organizational awareness and empathy), and relationship 
management (personnel development, conflict resolution, and teambuilding), are all 
components of emotional intelligence (Goleman et al., 2002) an effective public health 
leader will need to develop and practice when guiding an organization to implement or 
advocate for new HIV prevention methods.  
 Various leadership styles are preferential in different situations and the most 
effective leaders are able to switch between styles depending on the task or goal at 
hand (Goleman et al., 2002). Whether a public health leader is:  
 Visionary- helping others to see the larger picture 
 Coaching- promoting others’ personal development 
 Affiliative- responding to others’ emotional needs 
 Democratic- emphasizing collaboration and valuing input from others 
 Pace setting- constantly striving for optimal performance at the risk of personnel 
feelings, or  
 Commanding, delegating without explanation 
he or she will likely find changing leadership styles to meet varying demands or goals 
will achieve better results (Goleman et al., 2002), not just among staff, but for recipients 
of the organization’s outputs. A public health leader influences not just employees who 
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may be researching or promoting pre-exposure chemoprophylaxis, but also research or 
program participants, legislators, or clients.  
 
Leadership challenges. 
Even the most experienced public health leaders will face unexpected challenges 
when working to bring new HIV prevention strategies to people with few other options. 
Peters (2001) chronicled four common challenges faced by leadership staff: receiving 
limited information and options when approached to make a decision, not finding out 
about critical information until too late, being sheltered from negative information, and 
publically delaying truly important decisions for extended periods of time until they 
would be well received. Despite these difficult situations, Peters (2001) believed “silver 
linings” existed which leaders could use to their advantage. Public health leaders may 
experience all or none of these challenges when working towards a goal of making pre-
exposure chemoprophylaxis available for people who have no other options for HIV 
prevention. While there may only be one option to consider now, time will bring 
additional choices to make which will collectively influence the overall outcome (Peters, 
2001). Viewing each challenge as an opportunity to shape or enforce organizational 
values may allow both the public health leader and organization to overcome each 
challenge and more forward successfully (Peters, 2001). 
 
Proceeding with caution. 
The significant discovery of effective pre-exposure chemoprophylaxis is exciting 
and promising for both public health leaders and people with limited HIV prevention 
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opportunities, yet it requires proceeding with caution when deciding how to spend 
funding and which potential recipients to target. Wegbreit, Bertozzi, DeMaria, and 
Padian (2006) suggested the promotion and distribution of condoms as well as 
voluntary counseling and testing for HIV should be promoted for individuals at high risk, 
subpopulations at risk, or entire populations based on UNAIDS epidemic profiles. 
Enforcing stereotypes of subpopulations creates social harms when public health 
programs are not implemented fairly for all who may be at risk (Kass, 2001). When 
resources are spent to target only a subpopulation, even if the chosen subpopulation 
contains those most at risk, the at-risk subpopulation may experience continued 
stigmatization by the rest of the population (Forsythe, Stover, & Bollinger, 2009). In their 
efforts to promote HIV prevention strategies, public health leaders may consider how 
their messages will be received by both the targeted recipients and the general 
population.  
 
Future research and planning. 
Future research to improve and enhance HIV prevention methods may involve 
researching optimal dosing given HIV exposure risks. Previous mathematical models 
and clinical research have been based on an assumption of daily dosing for pre-
exposure chemoprophylaxis (Desai et al., 2008; Grant et al., 2010; Paltiel et al., 2009). 
While commercial sex workers and those injecting intravenous drugs may be exposed 
to HIV on a daily basis, other people at high risk for HIV infection may have less 
frequent exposure (van Griensven et al., 2010). A survey of MSM in Bangkok, Thailand 
found two-thirds of respondents planned their last act of sexual intercourse before it 
happened and most respondents engaged in sexual intercourse two days a week or 
BENEFITS OF HIV PRE-EXPOSURE CHEMOPROPHYLAXIS 
25 
 
less (van Griensven et al., 2010). This intermittent exposure to HIV suggests a need for 
intermittent pre-exposure chemoprophylaxis (van Griensven et al., 2010). If intermittent 
pre-exposure chemoprophylaxis was found to be efficacious, recipients would have to 
take fewer pills each week, would be subject to fewer side effects and toxicities, and 
would be faced with significantly less cost (van Griensven et al., 2010). Intermittent pre-
exposure chemoprophylaxis has been considered by researchers and should remain a 
priority for upcoming clinical trials (van Griensven et al., 2010). 
 
Recommendations 
People living in developed and developing countries alike may benefit from 
access to pre-exposure chemoprophylaxis as a potential option to gain control over their 
own risks for developing HIV infections when no other prevention methods are 
available. Regardless of individual risk factors for HIV exposure, public health leaders 
may consider working towards a long-term goal of making pre-exposure 
chemoprophylaxis an obtainable choice for anyone at risk who has no other option for 
prevention. Promotion of pre-exposure chemoprophylaxis along with other HIV 
prevention strategies could help to reduce the incidence rate of HIV in many 
communities worldwide. 
Stakeholders who would potentially benefit from global distribution of pre-
exposure chemoprophylaxis include not only those most at risk for acquiring HIV 
infections, but their family members, friends, neighbors, employers, and health care 
providers. Those most likely to support providing affordable pre-exposure 
chemoprophylaxis for people with no other options for HIV prevention are the people 
most affected by virus, specifically those at risk for infection and their household 
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members. To reach an altruistic global goal of providing pre-exposure 
chemoprophylaxis for all people worldwide who have no other options for HIV 
prevention, both public health and government leadership may be motivated to respond 
after viewing the task as one which requires an ethical obligation to act regardless of 
any perceived benefits or consequences. Reviewing ethical frameworks and moral 
theories may provide public health leaders with a context for evaluating new HIV 
prevention strategies and the potential consequences of including pre-exposure 
chemoprophylaxis in future program planning. After considering their potential actions 
through a lens of ethical theory, public health leaders may gain important insight into 
what the consequences may be for individuals in need of new methods for HIV 
prevention whether public health leaders choose to act or not. Leading and engaging in 
dialogue about which gaps exist in current HIV prevention programming and research 
may help public health leaders to decide to act upon a desire to bring new HIV 
prevention strategies to people who have no available methods for HIV prevention.  
As public health leaders work to make pre-exposure chemoprophylaxis available 
for people around the world who have no other options for HIV prevention, the following 
recommendations are suggested for consideration by leaders in public health research, 
public health policy, and public health programming: 
 provide education for the general public, law makers, and other public health 
leaders on what pre-exposure chemoprophylaxis is and who may benefit 
 review distribution models for PEP when planning methods to distribute pre-
exposure chemoprophylaxis to priority groups at public health organizations 
working towards making pre-exposure chemoprophylaxis availability a reality 
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 practice emotional intelligence while employing multiple leadership styles 
 promote and lead research projects to continue advancing HIV prevention 
methods. 
 
The importance of education. 
Recommendation 1.1: provide education for law makers and public health 
leaders to explain the gaps in policies and programming that promote pre-
exposure chemoprophylaxis for HIV. 
 The high predicted cost of an HIV chemoprophylaxis may encourage government 
officials and public health program planners to argue against providing the medication 
for free or at a subsidized cost citing common knowledge of low cost behavioral 
interventions known to prevent or limit exposure to HIV. Educating the government and 
public health leadership about the reasons why these preventative methods alone are 
not effective for all people at risk for HIV infection will strengthen the argument in favor 
of distribution of affordable pre-exposure chemoprophylaxis in tandem with previously 
proven prevention strategies. If lawmakers are unfamiliar with the often complex 
situations in which current HIV behavior prevention strategies are not realistic for some 
people at risk, public health leaders face the important task of working to educate them 
so they better understand why pre-exposure chemoprophylaxis is so important. 
Educational methods for brining awareness to US lawmakers of the daily lives for those 
living domestically and abroad at risk of HIV infection include: inviting people at risk to 
share personal accounts by writing a brief narrative or recording an oral depiction of 
their daily lives and risk factors, sharing photographs of the built environments and the 
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situations that may place people at risk for HIV exposure, and including short narratives 
of healthcare workers in communities with a high prevalence of HIV. Attaching human 
faces to the HIV pandemic may appeal to legislators who have little direct experience 
with HIV.  
When debating which HIV prevention strategies to devote funding to, the right 
thing for legislators to do is consider which strategies will bring the greatest benefit to 
their recipients, whether those strategies include pre-exposure chemoprophylaxis or 
not. Take the previously stated example of women at risk for HIV infections. In some 
situations, women are unable to negotiate condom use, choose their sexual partners, or 
question their partners about their serostatus. For these women at risk, pre-exposure 
chemoprophylaxis may offer the only HIV prevention strategy entirely in their control. 
For a young man living in a large metropolitan area whose HIV exposure risk factors 
include multiple sexual partners and illegal substance use when partying on the 
weekends, the most appropriate HIV prevention strategy may be risk reduction 
counseling and encouragement to use behavioral modifications. If public health leaders 
are able to educate legislatures and program planners on the appropriate uses of 
various HIV prevention strategies, legislatures will be better equipped to make policy 
decisions and allocate funding.  
 
Recommendation 1.2: continue to promote funding for ARV treatment 
programs while anticipating and responding to the concerns of those living with 
HIV who fear funding for pre-exposure chemoprophylaxis will limit their ability to 
receive affordable ARVs.  
BENEFITS OF HIV PRE-EXPOSURE CHEMOPROPHYLAXIS 
29 
 
To promote the greatest public good, governments and public health leadership 
who remain as committed to treating HIV infections as they are to preventing new 
infections, will be able to provide help to the most people possible. Those living with HIV 
who lack access to ARV treatment may feel marginalized, ignored, or resentful if HIV 
negative members of their communities are given free or affordable pre-exposure 
chemoprophylaxis. Further, fiscally conservative legislatures may wonder whether 
insurance companies or governments should be responsible for subsidizing the 
expensive monthly cost. Responding to these potential concerns with public health 
education campaigns may convince people of the importance pre-exposure 
chemoprophylaxis holds for people with no other options for HIV prevention. While 
arguments based on ethical theories may appeal to some, others may respond to 
messages rooted in humanitarian appeals. Public service announcements that address 
the concerns of people living with HIV who may be upset at the prospect of providing 
pre-exposure chemoprophylaxis at the risk of not providing ARV treatment for all who 
need it, may involve messages that include the promotion of protecting from infection 
one’s sexual partners, family members including children and grandchildren, friends, 
colleagues, and neighbors. Regularly communicating with stakeholders about program 
objectives, targeted participants, and number of clients served, may encourage 
community members to support the HIV prevention program even if they may not 
directly benefit themselves.  
 
Recommendation 1.3: provide education for the general public about pre-
exposure chemoprophylaxis.  
BENEFITS OF HIV PRE-EXPOSURE CHEMOPROPHYLAXIS 
30 
 
Just as with the introduction of the female condom in Africa, communities around 
the world may be leery of pre-exposure chemoprophylaxis upon its initial debut. Public 
health leaders can anticipate concerns and respond quickly with educational campaigns 
to rumors created out of fear, misunderstanding, or malice. Qualitative data collected 
during focus groups with people living in geographic areas with a high prevalence of 
HIV may help public health leaders to better understand what some of the potential 
responses to pre-exposure chemoprophylaxis use in the community may be. Even 
though a patient and her healthcare provider may have decided pre-exposure 
chemoprophylaxis is an appropriate strategy to protect her from HIV, the patient may 
still be influenced by the opinions of family and community members who are not as 
knowledgeable about pre-exposure chemoprophylaxis. Media campaigns including 
public service announcements on the radio, advertisements in newspapers, billboards, 
paintings on public buildings, messages printed on popular consumer products such as 
Coca-Cola bottles, and advertisements on public transportation vehicles could all 
promote healthy, factual messages about pre-exposure chemoprophylaxis while 
featuring members of the target audience.  
Targeting a pre-exposure chemoprophylaxis campaign at only specific 
subpopulations may send a message to people not in the targeted groups that they are 
not at risk for acquiring an HIV infection and need not consider behaviors to reduce or 
limit their exposure to HIV. While true that in some communities the prevalence of HIV 
is mostly limited to certain subpopulations, creating a general awareness of pre-
exposure chemoprophylaxis in the entire community may prevent stigmatization of 
individuals taking pre-exposure chemoprophylaxis and help those not in the most at risk 
BENEFITS OF HIV PRE-EXPOSURE CHEMOPROPHYLAXIS 
31 
 
groups to realize their own risk for HIV exposure. Including messages about pre-
exposure chemoprophylaxis in addition to, rather than instead of, those that promote 
other HIV prevention behavioral modifications will ensure a comprehensive HIV 
prevention campaign relevant for all members of the community.  
 
Benefits of policy discussions. 
Public health messages spread in the general population about pre-exposure 
chemoprophylaxis may promote a general awareness of the treatment to government 
leaders and legislators even if they are not at risk for acquiring HIV infection. While 
legislators may not be convinced of an ethical obligation to create public policies 
promoting the domestic and international distribution of pre-exposure chemoprophylaxis 
for people who have no other options for HIV prevention, there are possible benefits 
that can be derived from their participation in the policy discussions. Whether ultimately 
in favor of or against government funding for pre-exposure chemoprophylaxis, law 
makers will hopefully increase their awareness of HIV prevalence and incidence, better 
understand why current HIV prevention methods are inadequate for some individuals at 
risk of HIV infection, and consider the consequences of not providing pre-exposure 
chemoprophylaxis for HIV. An increased awareness of the potential benefits that could 
be derived from additional HIV prevention strategies could increase the likelihood 
legislators choose to support similar initiatives when they are proposed again in the 
future.  
 
Distribution planning. 
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Recommendation 2: consider PEP distribution models when planning for 
the distribution of pre-exposure chemoprophylaxis. 
With public health media campaigns to bring awareness of pre-exposure 
chemoprophylaxis to both the target population and general public, healthcare providers 
may experience an increase in the number of people asking about the preventative 
treatment. In the event there are limited resources available to provide pre-exposure 
chemoprophylaxis to people with frequent exposure to HIV and no ability to practice 
behavioral prevention methods, a formal plan could determine the most effective and 
fair method for distribution. Review of previously implemented PEP distribution models 
may provide public health leadership with guidance for developing pre-exposure 
chemoprophylaxis distribution policies by providing an example for what has worked in 
the past to attempt to prevent HIV infection in individuals after exposure to HIV. With 
limited resources available for implementing nearly any type of public health program, 
learning from the evaluation of prior programming can yield suggestions on ways to 
implement effective programs in the future.   
One first step for public health leadership to consider would be to make pre-
exposure chemoprophylaxis available to those with frequent exposure to HIV, who are 
otherwise unable to prevent infection using behavioral interventions, and are living in 
geographic areas with the highest HIV prevalence. For example, in a country or region 
with a low level epidemic risk in which the HIV prevalence in the general population is 
low but the prevalence in high risk groups such as MSM, sex workers, or injection drug 
users is higher, pre-exposure chemoprophylaxis use would be encouraged for only 
those individuals in the highest risk groups. On the other end of the epidemic risk profile 
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are countries in which the epidemic risk profile reveals a high prevalence among the 
general population. In these communities, pre-exposure chemoprophylaxis campaigns 
would be targeted at the general population and medication use encouraged only for 
individuals with more than sporadic exposure to HIV and limited options for HIV 
prevention. Appealing to nongovernmental organizations, governments, the Global 
Health Initiative, and other organizations that currently provide ARV therapy in these 
countries to ask that they consider providing funding for pre-exposure 
chemoprophylaxis may provide additional financial resources public health leaders can 
count on for future HIV prevention programming.  
   
Leadership styles. 
Recommendation 3.1: employ multiple leadership styles for effective 
lobbying, planning, and employee management for public health organizations 
working towards making pre-exposure chemoprophylaxis availability a reality. 
When working to implement new public health HIV prevention programs, 
research new HIV prevention methods, or to lobby government leaders to propose 
changes to current HIV/AIDs related policies, public health leaders may benefit from 
taking time to evaluate their current leadership strategies. Considering a change in 
leadership style may increase effectiveness when implementing programs, reaching 
goals, or working to produce positive changes among staff or legislators. Public health 
leaders may find they are able to better motivate employees, help others to share in the 
organization’s vision, or respond quickly in a crisis when leadership styles are tailored to 
the demands of a particular situation. When moving forward with HIV prevention 
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program planning, recommendations for implementing the different leadership styles as 
previously described include application of the following strategies: 
 Visionary strategies: help organization team members and community 
stakeholders to see how they contribute to the big picture of reducing global HIV 
incidence rates; give consideration to nonconventional tactics for HIV prevention 
education campaigns; remind employees why and how their work matters for 
those individuals who have limited options for HIV prevention. Team members 
who understand how their work benefits individuals who would benefit from 
additional HIV prevention options may be more inclined to complete additional 
tasks or put in extra effort on a project. These employees in turn may set a 
positive example for the other team members around them.  
 Coaching strategies: conduct one-on-one discussions with individual employees 
to discover what motivates employees and what career or educational goals they 
may have; recognize that not all employees desire a career in public health or in 
HIV/AIDs specifically and may have outside goals yet are still valuable to the 
organization while they are part of it; assist employees in reaching personal goals 
through mentoring, offer time off or financial assistance to attend relevant 
educational opportunities in the realm of public health, leadership, disease 
prevention, or other specific work related tasks when possible; help interested 
employees to discover job enhancing opportunities within the organization by 
allowing them the opportunities to expand their current roles; encourage 
employees when they show progress towards their goals. Employees who are 
convinced of their value to the organization are likely to be motivated to work 
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effectively to implement public health programming for HIV and may ultimately 
benefit more individuals through their work.  
 Affiliative strategies: gain awareness of the emotional needs of employees 
through conversation and observation; when possible, demonstrate flexibility 
when employee’s personal needs conflict with work obligations; encourage team 
building among staff, especially staff members who work together on the same 
HIV prevention or policy related projects or whose projects could benefit from 
collaboration with other staff members. Employees who feel their supervisor 
cares about them are likely to be motivated to work their hardest to meet 
organizational goals and may be more likely to respond to program participants 
or clients with caring and empathy. Program participants who are treated kindly 
and feel their concerns are validated by program staff may be more likely to 
encourage other community members to patronize the public health program as 
well.  
 Democratic strategies: acknowledge that leadership alone does not have all the 
answers to solve every one of the day to day or long-term problems that arise; 
solicit suggestions from staff and stakeholders during HIV prevention program 
planning, advocacy strategy meetings or during regular staff meetings; remain 
open-minded to employee suggestions and be willing to try new tactics when all 
else fails. Team members and stakeholders who feel their suggestions matter 
and are considered by management may be more likely to make additional 
suggestions in the future.  Not every suggestion made will be one that is worth 
acting upon, but the more opportunities that exist for employees and community 
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members to present their ideas, the likelihood increases that a suggestion worth 
exploring further is made.  
 Pace setting strategies: work to achieve immediate goals, especially when 
deadlines are strict, by keeping staff on task and intervening when the group or 
individual employees are distracted; after goals are met recognize employee 
efforts especially if staff members put forth extra effort or time on a particular 
project; if future project timelines allow, consider switching to one of the above 
leadership styles which may help employees to feel more relaxed and valued. A 
time to use pace setting strategies may be when a grant application is due on a 
strict timeline or when a large amount of data needs to be collected 
systematically in a short period of time. Pace setting leadership strategies can 
effectively guide team members during a short-term assignment but some 
employees may be better motivated when public health leaders employ the 
above leadership strategies most of the time.  
 Commanding strategies: reserve the commanding leadership style for times of 
crisis or when a situation requires constant monitoring and control. Extreme 
situations which may warrant use of this style might involve the opportunity to 
prepare an immediate reaction to a protest or rumors about HIV related issues in 
the community or the need to immediately stop a clinical trial of a pre-exposure 
chemoprophylaxis agent. Effective leaders may consider switching to another 
leadership style when the crisis at hand is under control. Employees who feel 
they are constantly being told what to do may not feel motivated to express new 
ideas or feel as if they are valued by the team.  
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Emotional intelligence. 
Recommendation 3.2: practice emotional intelligence to better motivate 
and encourage public health organization staff who will in turn be better equipped 
to lobby, research, and implement programs for pre-exposure chemoprophylaxis. 
In addition to varying leadership styles, effective public health leaders who work 
to achieve and maintain emotional intelligence may find they are able to lead their 
teams to success without having to resort to pace-setting or commanding leadership 
styles even in times of added pressure, tight deadlines, or emergency. While working to 
achieve emotional intelligence, a public health leader may find taking time for self 
reflection, goal setting, and self-care may leave him or her with the mental focus 
required to maintain emotional control, react to situations with empathy, and maintain 
relationships with peers and staff. An emotionally intelligent leader is better equipped to 
lead others towards a global goal of reducing HIV incidence. Both program staff and 
participants will benefit from an emotionally intelligent leader.  
 
Future research. 
Recommendation 4: promote and lead research projects to continue 
advancing HIV prevention methods. 
When public health leaders consider future research and program goals to 
reduce HIV incidence, considering the individual needs of program recipients is 
important. Many people who would initially take pre-exposure chemoprophylaxis would 
likely not be good candidates to continue the medication for their entire lives. As risk 
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factors for HIV infection change during their lifetimes, patients and their healthcare 
providers may decide taking pre-exposure chemoprophylaxis is not in the patient’s best 
interest at that time. Considering the frequency of individuals’ exposure to HIV, 
researching options for pre-exposure chemoprophylaxis to better fit into the lifestyle of 
the recipients yet still be effective is worth consideration for government funding. 
Effective public health leaders who regularly review and evaluate program data and 
available data sets of community HIV prevalence and incidence rates may find they are 
better equipped to propose new areas for research to fill HIV prevention gaps.  
Hermann Briggs once noted, “Public Health is purchasable. Within natural 
limitations every community can determine its own death rate” (Gostin, 2000). Briggs 
expressed this notion in 1894 (Gostin, 2000), many years before the discovery of HIV 
and the start of the pandemic which has claimed lives in every community across the 
globe. The choice to provide affordable pre-exposure chemoprophylaxis for women who 
have no other options for HIV prevention is the responsibility of leaders in public health, 
government officials, donors, and anyone who elects a public leader.  
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